POlymorphisms of Killer immunoglobulin-like receptor which affect Stop Tyrosine kinase Inhibitor in patients with Chronic myeloid leukemia: POKSTIC; mutlticenter collaborative observational study

POlymorphisms of Killer immunoglobulin-like receptor which affect Stop Tyrosine kinase Inhibitor in patients with Chronic myeloid leukemia: POKSTIC; mutlticenter collaborative observational study - POKSTIC study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041798

Enrollment

150

Registered

2020-09-16

Start date

2020-04-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Myeloid Leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were previously enrolled in TKI discontinuation trials (DADI, DOMEST and first-line DADI) and regularly observed. Patients who give informed consent.

Exclusion criteria

Exclusion criteria: Patients who can not give informed consent. Patients who were defined as appropriate by attending physician.

Design outcomes

Primary

Measure	Time frame
Polymorphisms of KIR for TFR	—

Secondary

Measure	Time frame
Polymorphisms of HLA for TFR Haplotypes (KIR and HLA) for TFR Polymorphisms of KIR and features of anti-tumor immunity	—

Countries

Japan

Contacts

Public ContactUreshino Hiroshi

Saga University Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine,

sr0795@cc.saga-u.ac.jp0952-34-2366

Outcome results